The Bader lab uses molecular interaction, pathway and 'omics data to gain a ‘causal’ mechanistic understanding of normal and disease phenotypes. They are developing novel computational approaches that combine molecular interaction and pathway information with ‘omics data to develop clinically predictive models and identify therapeutically targetable pathways. This research, for instance, helped identify a histone methylation inhibitor as the first therapeutic candidate for pediatric ependymoma, a common childhood brain cancer (collaboration with Michael Taylor at SickKids).
Dr. Bader completed postdoctoral work in the group of Chris Sander in the Computational Biology Center (cBio) at Memorial Sloan-Kettering Cancer Center in New York. He obtained his PhD in the lab of Christopher Hogue in the Department of Biochemistry at the University of Toronto and the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto. He completed a BSc in Biochemistry at McGill University in Montreal.
- Professor, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto
- Professor, Department of Molecular Genetics, University of Toronto
- Professor, Department of Computer Science, University of Toronto
- Associate Member, Lunenfeld-Tanenbaum Research Institute, Sinai Health System